EVEROLIMUS (RAD001) AND THE MTOR PATHWAY IN LOW-GRADE GLIOMAS

被引：0
|
作者：
Clarke, Jennifer L. [1 ]
Chang, Susan [1 ]
Phillips, Joanna [1 ]
Molinaro, Annette [1 ]
Berger, Mitchel [1 ]
Nelson, Sarah [1 ]
Haas-Kogan, Daphne [1 ]
机构：
[1] Univ Calif San Francisco, San Francisco, CA 94143 USA
来源：
NEURO-ONCOLOGY | 2014年 / 16卷
关键词：
D O I：
10.1093/neuonc/nou209.24
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Biomarker Development for the Clinical Activity of the mTOR Inhibitor Everolimus (RAD001): Processes, Limitations, and Further Proposals
    O'Reilly, Terence
    McSheehy, Paul M. J.
    TRANSLATIONAL ONCOLOGY, 2010, 3 (02): : 65 - 79
  • [22] RAD001 (Everolimus) in Liver Transplantation - A Rational Approach To Quantify and Predict the mTOR Treatment Effect.
    Junge, G.
    Dumortier, T.
    Fischer, L.
    Schwende, H.
    Fung, J.
    LIVER TRANSPLANTATION, 2013, 19 : S165 - S165
  • [23] Activity of mTOR-Inhibitor Rad001 (everolimus) in differentiated and anaplastic thyroid cancer cell lines
    Behlendorf, T.
    Voigt, W.
    Mueller, T.
    Jordan, K.
    Arnold, D.
    Schmoll, H.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [24] A Phase Ib Study Combining the mTOR Inhibitor Everolimus (RAD001) with Low-Dose Cytarabine In Untreated Elderly AML
    Wei, Andrew H.
    Sadawarte, Sonali
    Catalano, John
    Hills, Robert
    Avery, Sharon
    Patil, Sushrut S.
    Burnett, Alan
    Spencer, Andrew
    BLOOD, 2010, 116 (21) : 1351 - 1352
  • [25] FINAL RESULTS OF A PROSPECTIVE MULTI-INSTITUTIONAL PHASE II STUDY OF EVEROLIMUS (RAD001), AN MTOR INHIBITOR, IN PEDIATRIC PATIENTS WITH RECURRENT OR PROGRESSIVE LOW-GRADE GLIOMA. A POETIC CONSORTIUM TRIAL
    Kieran, Mark W.
    Yao, X.
    Macy, M.
    Leary, S.
    Cohen, K.
    MacDonald, T.
    Allen, J.
    Boklan, J.
    Smith, A.
    Nazemi, K.
    Gore, L.
    Trippett, T.
    DiRenzo, J.
    Narendran, A.
    Perentesis, J.
    Prabhu, S.
    Pinches, N.
    Robison, N.
    Manley, P.
    Chi, S.
    NEURO-ONCOLOGY, 2014, 16
  • [26] Prospective, Multicenter Study of the MTOR Inhibitor Everolimus (RAD001) As Primary Therapy in Waldenstrom's Macroglobulinemia
    Treon, Steven P.
    Tripsas, Christina K.
    Ioakimidis, Leukothea
    Warren, Diane
    Patterson, Christopher
    Heffner, Leonard
    Eradat, Herbert
    Gregory, Stephanie A.
    Thomas, Sheeba
    Advani, Ranjana
    Baz, Rachid
    Badros, Ashraf Z.
    Matous, Jeffrey
    Anderson, Kenneth C.
    Ghobrial, Irene M.
    BLOOD, 2011, 118 (21) : 1273 - 1274
  • [27] Everolimus (RAD001) Treatment Effect in Liver Transplantation - A Rational Approach To Quantify the mTOR Effect.
    Junge, G.
    Dumortier, T.
    Fischer, L.
    Kohler, S.
    Fung, J.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2013, 13 : 504 - 505
  • [28] Phase II trial of the oral mTOR inhibitor everolimus (RAD001) for patients with relapsed or refractory lymphoma
    Johnston, P. B.
    Ansell, S. M.
    Colgan, J. P.
    Habermann, T. M.
    Inwards, D. J.
    Markovic, S. N.
    Micallef, I. N.
    Porrata, L. F.
    LaPlant, B. R.
    Geyer, S. M.
    Witzig, T. E.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [29] The activity of mTOR inhibitor RAD001 (everolimus) in nasopharyngeal carcinoma and cisplatin-resistant cell lines
    Ma, Brigette B. Y.
    Lui, Vivian W. Y.
    Hui, Edwin P.
    Lau, Cecilia P. Y.
    Ho, Kakiu
    Ng, Margaret H. L.
    Cheng, S. H.
    Tsao, Sai-Wah
    Chan, Anthony T. C.
    INVESTIGATIONAL NEW DRUGS, 2010, 28 (04) : 413 - 420
  • [30] Upfront treatment with mTOR inhibitor everolimus in pediatric low-grade gliomas: A single-center experience
    Cacchione, Antonella
    Lodi, Mariachiara
    Carai, Andrea
    Miele, Evelina
    Tartaglia, Marco
    Megaro, Giacomina
    Del Baldo, Giada
    Alessi, Iside
    Colafati, Giovanna Stefania
    Carboni, Alessia
    Boccuto, Luigi
    Camassei, Francesca Diomedi
    Catanzaro, Giuseppina
    Po, Agnese
    Ferretti, Elisabetta
    Pedace, Lucia
    Pizzi, Simone
    Folgiero, Valentina
    Pezzullo, Marco
    Corsetti, Tiziana
    Secco, Domitilla Elena
    Cefalo, Maria Giuseppina
    Locatelli, Franco
    Mastronuzzi, Angela
    INTERNATIONAL JOURNAL OF CANCER, 2021, 148 (10) : 2522 - 2534
12345